Quality of Life During and After Treatment of Hodgkin’s Disease

  • B. Hœrni
  • H. Eghbali
Conference paper
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 117)


During recent decades prognosis and survival in Hodgkin’s disease have improved strikingly. For all patients, the rate of cure is approximately 75% and for the majority, with limited disease (stage I-IIIA), it is nearly 90% (Zittoun et al. 1985). Improving the quality of life for the majority of patients has also been a basic aim in recent years (Hœrni et al. 1983; Eghbali and Hœrni-Simon 1984).


Clin Oncol Herpes Zoster Irradiate Area Personal Parameter Late Cardiac Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aaronson NK, Beckmann J (eds) (1987) The quality of life of cancer patients. Raven, New YorkGoogle Scholar
  2. Anonymous (1987) Who should treat Hodgkin“s disease and where? Lancet I: 605Google Scholar
  3. Behrendt H, Van Bunningen BNFM, Van Leeuwen EF (1987) Treatment of Hodgkin“s disease in children with or without radiotherapy. Cancer 59: 1870–1873PubMedCrossRefGoogle Scholar
  4. Bookman MA, Longo DL (1986) Concomitant illness in patients treated for Hodgkin“s disease. Cancer Treat Rev 13: 77–111PubMedCrossRefGoogle Scholar
  5. Brämswig JH, Heiermann E, Heimes U, Schlegel W, Nieschlag E, Schellong G (1987) Testicular function in boys treated for Hodgkin“s disease. Prospective evaluation in 68 boys of the DAL-HD-78 and DAL-HD-82 therapy study. Third International Conference on Malignant Lymphoma, Lugano (abstr p 25 )Google Scholar
  6. Chauvergne J, Hcerni B, Hcerni-Simon G, Durand M, Lagarde C (1973) Chimiothérapie de la maladie de Hodgkin associant procarbazine, vinblastine, cyclophosphamide et méthylprednisolone. Analyse d“une série de 124 cures. Z Krebsforsch 80: 179–188CrossRefGoogle Scholar
  7. Combes PF, Desclaux B, Malissard L, Pons A (1977) Poids du diagnostic de maladie de Hodgkin sur la qualité de la vie des sujets qui en sont guéris. Bull Cancer (Paris) 64: 395–408Google Scholar
  8. Cosset JM, Henry-Amar M, Ozanne F, Le Bourgeois JP (1984) Les péricardites radiques. Etudes des cas observés dans une série de 160 maladies de Hodgkin irradiées en mantelet à l“Institut Gustave-Roussy, de 1976 à 1980. J Eur Radiothérapie 5: 297–308Google Scholar
  9. Eghbali H, Hcerni-Simon G (1984) Qualité de la vie et maladie de Hodgkin. In: Schraub S, Brugère J, Hcerni B (eds) Qualité de la vie et cancers. Progrès en cancérologie, 4. Doin, Paris, pp 283–290Google Scholar
  10. Ferme C, Teillet F, d“Agay MF, Gisselbrecht C, Marty M, Boiron M (1984) Combined modality in Hodgkin“s disease. Comparison of six versus three courses of MOPP with clinical and surgical restaging. Cancer 54: 2324–2329Google Scholar
  11. Fobair P, Hoppe RT, Bloom J, Cox R, Varghese A, Spiegel D (1986) Psychosocial problems among survivors of Hodgkin“s disease. J Clin Oncol 4: 805–814PubMedGoogle Scholar
  12. Gallez-Marchal D, Fayolle M, Henry-Amar M, Le Bourgeois JP, Rougier P, Cosset JM (1984) Radiation injuries of the gastrointestinal tract in Hodgkin“s disease: the role of exploratory laparotomy and fractionation. A study of 19 cases observed in a series of 134 patients treated at the Institut Gustave-Roussy from 1972 to 1982. Radiother Oncol 2: 93–99PubMedCrossRefGoogle Scholar
  13. Guinee VF, Guido JJ, Pfalzgraf KA et al. (1985) The incidence of herpes zoster in patients with Hodgkin“s disease. An analysis of prognostic factors. Cancer 56: 642–648PubMedCrossRefGoogle Scholar
  14. Henry-Amar M (1988) Quantitative risk of second cancer in patients in first complete remis-sion from early stages of Hodgkin“s disease. NCI Monogr 6: 65–72PubMedGoogle Scholar
  15. Hcerni B (ed) (1982) L“information des personnes malades. SIMEP, Lyon-Villeurbanne Google Scholar
  16. Hcerni B for Groupe Pierre-et-Marie-Curie (1985) Enquête psychosociale chez 28 adolescents traités pour une maladie de Hodgkin. Psychol Med 17: 1975–1976Google Scholar
  17. Hcerni B, Hcerni-Simon G, Eghbali H, Richaud P (1983) Qualité de vie pendant et après association radio-chimiothérapique pour maladie de Hodgkin. Appréciation de 60 malades. Bull Cancer (Paris) 70: 284–288Google Scholar
  18. Hcerni B, Zittoun R, Rojouan J et al. (1986a) Information des malades traités pour une maladie de Hodgkin. Liaisons avec la qualité de vie. Bull Cancer (Paris) 73: 305–310Google Scholar
  19. Hcerni B, Zittoun R, Rojouan J et al. (1986 b) Retentissement psychosocial du traitement de la maladie de Hodgkin. Appréciation par questionnaire auprès de 150 malades. Bull Cancer (Paris) 73: 620–626Google Scholar
  20. Hcerni B, Orgerie MB, Eghbali H et al. (1988) Nouvelle association d“epirubicine, bléomycine, vinblastine et prednisone (EBVPII) avant radiothérapie dans les stades localisés de maladie de Hodgkin. Essai de phase II chez 50 malades. Bull Cancer (Paris) 75: 789–794Google Scholar
  21. Hcerni-Simon G, Zittoun R (1985) Coût thérapeutique et qualité de vie pendant et après le traitement d“une maladie de Hodgkin. In: Hcerni-Simon G, Gisselbrecht C (eds) Maladie de Hodgkin. Progrès en hématologie, 7. Doin, Paris, pp 179–191Google Scholar
  22. Jacobs C, Ross RD, Walker IM, Stockdale FE (1983) Behavior of cancer patients: a randomized study of the effects of education and peer support groups. Am J Clin Oncol 6: 347–353PubMedCrossRefGoogle Scholar
  23. Lagarde P, Eghbali H, Bonichon F et al. (1988) Brief chemotherapy associated with extended field radiotherapy in Hodgkin“s disease. Long-term results in a series of 102 patients with clinical stages I-IIIA. Eur J Cancer Clin Oncol 24: 1191–1198PubMedCrossRefGoogle Scholar
  24. Pohjola-Sintonen S, Tötterman KJ, Salmo M, Siltanen P (1987) Late cardiac effects of mediastinal radiotherapy in patients with Hodgkin“s disease. Cancer 60: 31–37PubMedCrossRefGoogle Scholar
  25. Santoro A, Bonfante V, Bonadonna G et al. (1981) Therapeutic and toxicologic effects of MOPP-ABVD combined with radiotherapy in Hodgkin“s disease. In: Salmon SE, Jones SE (eds) Adjuvant therapy of cancer III. Grune and Stratton, New York, pp 85–91Google Scholar
  26. Strull WM, Lo B, Charles G (1984) Do patients want to participate in medical decision making. JAMA 252: 2990–2994PubMedCrossRefGoogle Scholar
  27. Torti FM, Bristow MM, Lum BL et al. (1986) Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res 46: 3722–3727PubMedGoogle Scholar
  28. Wasserman AL, Thompson EI, Wilimas JA, Fairclough DL (1987) The psychological status of survivors of childhood/adolescent Hodgkin“s disease. Am J Dis Child 141: 626–631PubMedGoogle Scholar
  29. Zittoun R (1985) Indications thérapeutiques et processus décisionnel dans la maladie de Hodgkin. In: Hcerni-Simon G, Gisselbrecht C (eds) Maladie de Hodgkin. Progrès en Hématologie, 7. Doin, Paris, pp 193–215Google Scholar
  30. Zittoun R, Audebert A, Hcerni B et al. (1985) Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin“s disease. J Clin Oncol 3: 207–214PubMedGoogle Scholar
  31. Zittoun R, Eghbali H, Audebert A et al. (1987) Association d“épirubicine, bleomycine, vinblastine et prednisone (EBVP) avant radiothérapie dans les stades localisés de la maladie de Hodgkin. Essai de phase II. Bull Cancer (Paris) 74: 151–157Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1989

Authors and Affiliations

  • B. Hœrni
    • 1
  • H. Eghbali
    • 1
  1. 1.Fondation BergoniéBordeaux CedexFrance

Personalised recommendations